Total licensing revenue crosses $1.046 million; strategic collaboration with OncoX evolves toward expanded product development and global oncology footprint
SILICON VALLEY, CA - July 24, 2025 (NEWMEDIAWIRE) - ABVC BioPharma, Inc. (NASDAQ: ABVC), a clinical-stage biopharmaceutical company developing therapeutic solutions in ophthalmology, CNS (central nervous systems), and oncology/hematology, today announced receipt of a $100,000 milestone payment from OncoX BioPharma, Inc. under its strategic licensing agreement signed in 2024. With this latest payment, ABVC and its subsidiaries have now recorded a total of $1,046,000 in cumulative licensing income from AiBtl, ForSeeCon, and OncoX.
“This milestone payment builds upon the 2024 licensing agreement with OncoX, and reflects the shared belief that our strategic collaboration can lead to new product and market opportunities,” said Dr. Uttam Patil, ABVC's Chief Executive Officer. “These funds not only validate the commercial value of our late-stage oncology platform, but also support ongoing collaborative efforts aimed at expanding OncoX’s therapeutic focus and enhancing its market presence.”
“We’re excited to move into the next stage of collaboration with ABVC,” said Yen Wen Pin, CEO of OncoX BioPharma. “This milestone payment represents more than a transaction - it’s an investment in long-term innovation. We are actively working on broadening our oncology development programs, and the continued partnership with ABVC will help bring novel botanical-based treatments to global markets.”
Advancing Botanical Oncology
The OncoX agreement supports the development and global commercialization of botanical therapeutics in oncology, including preclinical programs with strong in vitro and early animal efficacy data. The broader deal value includes potential future milestone and royalty-based payments, contributing to ABVC’s long-term revenue outlook.
While the licensing agreements were initially executed in 2024, the partnership between ABVC and OncoX has expanded beyond the original licensing agreement to include joint business development initiatives focused on product line enhancement and potential market diversification.
Strategic Impact for Shareholders
This payment reinforces the Company's previously stated 2025 guidance, supported by prior achievements such as:
- 234% year-over-year increase in revenue (2024)
- 77% year-over-year improvement in earnings per share
- Total potential value of disclosed licensing agreements and related products estimated at over $959 million (AiBtl: $667M, OncoX: $105M, ForSeeCon: $187M)
These continued payments reflect growing market interest in ABVC’s differentiated drug development model. The OncoX collaboration is expected to drive future regulatory filings and commercialization opportunities in oncology.
Management believes the Company's product pipeline has excellent market potential. According to Precedence Research, the global cancer therapeutics market is projected to reach $393.61 billion by 2032, up from $164 billion in 2022, growing at a CAGR of 9.2%.[1]
About OncoX BioPharma
OncoX BioPharma is a clinical-stage biopharmaceutical company focused on developing next-generation cancer immunotherapies derived from natural sources. The company currently has three proprietary pipeline programs, including its lead product candidate targeting solid tumors and hematologic malignancies, which has demonstrated promising safety and efficacy in early-phase clinical studies and received four INDs (Investigational New Drug Applications) approved by the U.S. FDA. The Company believes that the estimated total market opportunity of its oncology pipeline, inclusive of its existing licensing agreements and assets, has the potential to reach $1 billion.
In addition to its therapeutic pipeline, OncoX is actively expanding into cancer-supportive care and preventative health through proprietary natural ingredients. The company has also acquired the Lycogen® extraction platform to enter adjacent fields including preventative medicine, chronic disease care (such as benign prostatic hyperplasia, diabetic wound healing), aesthetic medicine, and animal health. These cross‑sector applications are projected to reach a global market size of $187 million by 2030, according to Allied Market Research.[2]
OncoX operates under a strategic collaboration and manufacturing framework with BioKey Inc., a U.S. FDA-registered facility. The company is expanding its global footprint, with development and commercialization plans in the United States, Japan, Taiwan, and other key Asia-Pacific markets. OncoX is currently preparing for future clinical milestones and pursuing long-term international partnerships to bring its innovative therapies to patients worldwide.
About ABVC BioPharma & Its Industry
ABVC BioPharma is a clinical-stage biopharmaceutical company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus®) under development. For its drug products, the Company utilizes in-licensed technology from its network of world-renowned research institutions to conduct proof-of-concept trials through Phase II of clinical development. The Company's network of research institutions includes Stanford University, University of California at San Francisco, and Cedars-Sinai Medical Center. For Vitargus®, the Company intends to conduct pivotal clinical trials (Phase III) through global partnerships.
Forward-Looking Statements
This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential," or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions, and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified, and, consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. None of the outcomes expressed herein are guaranteed. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) our inability to manufacture our product candidates on a commercial scale on our own, or in collaboration with third parties; (ii) difficulties in obtaining financing on commercially reasonable terms; (iii) changes in the size and nature of our competition; (iv) loss of one or more key executives or scientists; and (v) difficulties in securing regulatory approval to proceed to the next level of the clinical trials or to market our product candidates. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission (SEC), including the Company's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Investors are urged to read these documents free of charge on the SEC's website at http://www.sec.gov. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.
This press release does not constitute an offer to sell, or the solicitation of an offer to buy any of the Company's securities, nor shall such securities be offered or sold in the United States absent registration or an applicable exemption from registration, nor shall there be any offer, solicitation or sale of any of the Company's securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such state or jurisdiction.
Contact:
Uttam Patil
Email: uttam@ambrivis.com
View the original release on www.newmediawire.com
